Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Total Non-Current Liabilities (2020 - 2025)

RxSight filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $32.9 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 7.56% to $32.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.9 million, a 7.56% decrease, with the full-year FY2025 number at $32.9 million, down 7.56% from a year prior.
  • Total Non-Current Liabilities hit $32.9 million in Q4 2025 for RxSight, up from $32.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $60.3 million in Q4 2022 to a low of $19.2 million in Q1 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $33.2 million (2024), compared with a mean of $36.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 63.3% in 2023 and later skyrocketed 75.34% in 2025.
  • RxSight's Total Non-Current Liabilities stood at $54.5 million in 2021, then rose by 10.62% to $60.3 million in 2022, then plummeted by 63.3% to $22.1 million in 2023, then surged by 61.1% to $35.6 million in 2024, then fell by 7.56% to $32.9 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $32.9 million (Q4 2025), $32.6 million (Q3 2025), and $31.0 million (Q2 2025) per Business Quant data.